Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hyperlipidemia: full-pipeline trial registry
4 of 36 indexed Hyperlipidemia trials are currently recruiting.
Corpus placement: #419 of 28,707 conditions by registered trial count.
36 US clinical trials · 4 currently recruiting · #419 of 28,707 conditions by registered trial count
Hyperlipidemia: 36 US clinical trials tracked, 4 recruiting.
Hyperlipidemia is the subject of 36 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 3 of these trials.
Enrollment posture brief
Registry condition hyperlipidemia
OPEN 4 | RECR 11% | LATE 11 | EARLY 10 | RANK #419 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Heart Failure (11% recruiting · 9 trials)
Hyperlipidemia lists 4 open slots (11% of 36 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hyperlipidemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hyperlipidemia is recruiting below its size-band peers.
4 of 36 indexed trials (11.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hyperlipidemia trials is spread across many organizations.
Amgen accounts for 3 of 36 trials (8.3%). 31 distinct sponsors appear on at least one study for this condition label.
-
Typical Hyperlipidemia enrolment sits around 156 participants.
Median target enrolment is 156 among the 36 trials that report a genuine target (sentinel values excluded). 13 of those (36.1%) plan for fewer than 100 participants.
-
Hyperlipidemia research is mostly interventional.
36 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
36 total, page 1 of 1
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Merck Sharp & Dohme
NCT07216482
Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
Colorado Prevention Center
NCT07334834
Inspire HER: Inspiring the Heart and Emotions for Radical Health
University of Alabama at Birmingham
NCT06966258
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
Indiana University
NCT07119658
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02262806
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02262832
Body Worlds 3 Nutrition Display
Oregon Health and Science University
NCT00669500
Improving Quality With Outpatient Decision Support
Agency for Healthcare Research and Quality (AHRQ)
NCT00225628
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
Pfizer
NCT00134173
Cholesterol and Pharmacogenetic Study
UCSF Benioff Children's Hospital Oakland
NCT00451828
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
Amgen
NCT01380730
Unmet Social Needs Study
VA Office of Research and Development
NCT04977583
The Health Access and Recovery Peer Program
Emory University
NCT01725815
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Amgen
NCT01763918
The SCCS Polypill Pilot Trial
Vanderbilt University
NCT02278471
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
Duke University
NCT00275145
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
Aegerion Pharmaceuticals
NCT00559962
Veterans Walk for Health Study
US Department of Veterans Affairs
NCT00123435
Federal Study of Adherence to Medications in the Elderly (FAME)
Walter Reed Army Medical Center
NCT00393419
Eating Peanuts for Health
Purdue University
NCT01886326
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
Daiichi Sankyo
NCT00484419
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Amgen
NCT01375764
Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes
US Department of Veterans Affairs
NCT00108459
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
Radiant Research
NCT01239004
Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management
Denver Health and Hospital Authority
NCT01391585
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects
Kowa Research Institute
NCT02676596
Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
Beijing Peking University WBL Biotech Co.
NCT01327014
Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention
Wake Forest University Health Sciences
NCT06647238
Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress
University of Mississippi Medical Center
NCT01267227
Telephone Based Management of Hyperlipidemia
Temple University
NCT01212159
The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes
Maine Center for Lipids and Cardiovascular Health
NCT00360217
Effects of Use of a Connected Pillbox On Medication Adherence
University of Pennsylvania
NCT02593032
Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study
Northwestern University
NCT00225017
Antihyperlipidemic Effects of Oyster Mushrooms
National Center for Complementary and Integrative Health (NCCIH)
NCT00069524
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The Miriam Hospital
NCT00887653
Biosynthesis of PGD2 in Vivo
University of Pennsylvania
NCT01275300
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
| Phase 3 | 8 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hyperlipidemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hyperlipidemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hyperlipidemia page
36 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Hyperlipidemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Hyperlipidemia trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperlipidemia condition card totals 36 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.